For instance, TNF-α had been a promising target in patients with severe RA, but up to two thirds of patients do not have a full response; in this group, targeting IL-6 is not only useful, but even improves the overall response to therapy of these patients [56]. Here, TNF is linked to rheumatoid arthritis.